Ring Therapeutics is revolutionizing the gene therapy and nucleic acid medicine space by harnessing the most abundant and diverse member of the human commensal virome, anelloviruses. The company developed the Anellogy™ platform which focuses on anelloviruses to potentially treat a broad range of diseases. Through harnessing the unique properties of these commensal viruses, the Anellogy™ platform generates diverse vectors that exhibit both tissue-specific tropism and the potential to be re-dosed. Ring Therapeutics, founded by Flagship Pioneering in 2017, aims to develop and further expand its portfolio by leveraging its platform to unlock the full potential of gene therapy and nucleic acid medicines, enabling a variety of mechanisms that successfully deliver therapeutic cargo to unreachable organs and tissues.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/09/23 | $86,500,000 | Series C |
Alexandria Venture Investments Altitude Life Science Ventures CJ Investment Flagship Pioneering Invus Kyowa Kirin Co. Partners Investment Co. T. Rowe Price Associates UPMC Enterprises | undisclosed |
